Literature DB >> 11223746

Comparison of ultrasound-guided biopsies and prostatectomy specimens: predictive accuracy of Gleason score and tumor site.

A Gregori1, J Vieweg, P Dahm, D F Paulson.   

Abstract

OBJECTIVE: To critically evaluate the accuracy of sextant biopsies in predicting Gleason score and the site of tumor location in patients with clinically localized prostate cancer treated by radical perineal prostatectomy.
METHODS: The case records of 289 patients with clinically localized prostate cancer who underwent radical perineal prostatectomy were reviewed, comparing the Gleason score and tumor site location as determined by sextant ultrasound-guided core biopsies with the Gleason score and tumor distribution within the surgical specimens. The prostatectomy specimens were further characterized by extent of disease as organ-confined, specimen-confined or margin-positive.
RESULTS: The Gleason score was identical in 126 (43.5%) patients. An upgrading in the surgical specimen occurred in 118 (40.8%) cases, a downgrading in 43 (14.8%). Overall, 193 (66.7%) patients had a unilateral positive biopsy, while 96 (33.2%) patients had bilateral positive biopsies. Sixty-four (33.1%) patients with a unilateral positive biopsy had cancer confined to one side of the gland, while 127 (65.8%) showed bilateral disease; 142 (73.5%) patients had organ-confined tumors versus 51 (26.4%) patients with capsular penetration. In the 96 patients with bilateral positive biopsies, 64 (66.6%) patients had intracapsular cancer versus 32 (33.3%) patients with either specimen-confined or margin-positive disease. The overall rate of positive margins was 14%. Fifty-one (61.4%) of the 83 patients with non-organ-confined disease had posterolateral capsular penetration in the region of the superior pedicle of the neurovascular bundle, while 28 (33.7%) patients had apical capsular penetration, in the region of the inferior neurovascular pedicle.
CONCLUSIONS: The ability of sextant ultrasound-guided biopsies to estimate the pathological grading is satisfactory: when we consider a difference of +/- 1 in the final Gleason score, the overall correlation is 80%. In 66% of the cases, sextant biopsies predicted unilateral disease when bilateral disease existed. A unilateral positive biopsy does not predict unilateral disease. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2001        PMID: 11223746     DOI: 10.1159/000056573

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  11 in total

1.  Focal therapy: a new paradigm for the treatment of prostate cancer.

Authors:  Basir Tareen; Guilherme Godoy; Samir S Taneja
Journal:  Rev Urol       Date:  2009

2.  Management of low-risk prostate cancer.

Authors:  Robert A Gardiner; Freddie C Hamdy
Journal:  World J Urol       Date:  2008-09-19       Impact factor: 4.226

3.  Endorectal MRI after radiation therapy: questioning the sextant analysis.

Authors:  Shilpa R Kumbhani; Fergus V Coakley; Charles E McCulloch; Z Jane Wang; John Kurhanewicz; Mack Roach; Antonio C Westphalen
Journal:  J Magn Reson Imaging       Date:  2011-05       Impact factor: 4.813

4.  Frequency and determinants of disagreement and error in gleason scores: a population-based study of prostate cancer.

Authors:  Michael Goodman; Kevin C Ward; Adeboye O Osunkoya; Milton W Datta; Daniel Luthringer; Andrew N Young; Katerina Marks; Vaunita Cohen; Jan C Kennedy; Michael J Haber; Mahul B Amin
Journal:  Prostate       Date:  2012-01-06       Impact factor: 4.104

Review 5.  Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?

Authors:  Hashim Uddin Ahmed; Mark Emberton
Journal:  World J Urol       Date:  2008-08-14       Impact factor: 4.226

6.  Pathological correlation between needle biopsy and radical prostatectomy specimen in patients with localized prostate cancer.

Authors:  Muhammad A Bulbul; Yaser El-Hout; Maurice Haddad; Ayman Tawil; Ali Houjaij; Nizar Bou Diab; Oussama Darwish
Journal:  Can Urol Assoc J       Date:  2007-09       Impact factor: 1.862

7.  Predictors of Gleason score upgrading in patients with prostate biopsy Gleason score ≤6.

Authors:  Hasmet Sarici; Onur Telli; Orhan Yigitbasi; Musa Ekici; Berat Cem Ozgur; Cem Nedim Yuceturk; Muzaffer Eroglu
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

8.  The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database.

Authors:  Ryan S Turley; Martha K Terris; Christopher J Kane; William J Aronson; Joseph C Presti; Christopher L Amling; Stephen J Freedland
Journal:  BJU Int       Date:  2008-09-03       Impact factor: 5.588

9.  Utility of extended pattern prostate biopsies for tumor localization: pathologic correlations after radical prostatectomy.

Authors:  Ryan T Schulte; David P Wood; Stephanie Daignault; Rajal B Shah; John T Wei
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

10.  Interobserver reproducibility of Gleason grading: evaluation using prostate cancer tissue microarrays.

Authors:  M Burchardt; R Engers; M Müller; T Burchardt; R Willers; J I Epstein; R Ackermann; H E Gabbert; A de la Taille; M A Rubin
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-08       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.